comprehensive -WSS

comprehensive

author：focus 2025-08-28 08:40:21 - browse：23

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Curing rare childhood diseases will falter unless Congress steps up

focus

WSS

A daunting task: navigating dual Medicare, Medicaid eligibility

ALS patient reclaims some autonomy thanks to wearable 'robot'

My daughter's legacy lives on through her writing, phage therapy

Surge of respiratory disease in China has likely explanation

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Medical device trials still don't enroll enough women, study finds

entertainment

comprehensive

leisure time

Walensky prepares to leave CDC — and Congress — behind

Report captures long Covid’s disabling effects and policy challenges

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Medicare details structure of new drug price negotiation program

CRISPR pioneers react to Casgevy, first gene

Hepatitis C has a cure — but many Americans still lack access to it

World's first CRISPR

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Study: Why relieving medical debt did not improve financial outcomes

leisure time

How faith leaders like me can help address America's obesity epidemic

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Does good food count as health care? Study aims to find out

Anthos stroke drug appears safer than common blood thinner

Medical device trials still don't enroll enough women, study finds

focus

explore

explore

focus